In addition, Ra Medical has granted the underwriters a 30-day option to purchase up to an additional 585,000 shares of common stock at the initial public offering price less underwriting discounts and commissions.
Ra Medical's common stock began trading on the New York Stock Exchange under the symbol "RMED" on September 27, 2018.
The offering is expected to close on October 1, 2018, subject to customary closing conditions.
Piper Jaffray and Co. and Cantor Fitzgerald and Co. are acting as lead joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. is acting as lead manager and Nomura Securities International, Inc. and Maxim Group LLC are acting as co-managers for the offering.
Ra Medical Systems was founded in 2002 to commercialise excimer lasers and catheters for the treatment of dermatologic and cardiovascular diseases.
Its flagship product, Pharos, launched in 2004.
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal
Sarepta Therapeutics commences Phase 3 clinical study of SRP-9003 for LGMD2E